MCID: PRK039
MIFTS: 55

Parkinsonism

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Parkinsonism

MalaCards integrated aliases for Parkinsonism:

Name: Parkinsonism 12 74 54 6
Parkinsonism-Plus 6

Classifications:



External Ids:

Disease Ontology 12 DOID:0080855
ICD10 32 G22

Summaries for Parkinsonism

Disease Ontology : 12 A movement disorder that is characterized by disturbances of balance, gait and posture.

MalaCards based summary : Parkinsonism, also known as parkinsonism-plus, is related to dystonia 3, torsion, x-linked and dystonia, dopa-responsive. An important gene associated with Parkinsonism is TBC1D24 (TBC1 Domain Family Member 24), and among its related pathways/superpathways are Pathways of neurodegeneration - multiple diseases and Neuroscience. The drugs Zonisamide and Tadalafil have been mentioned in the context of this disorder. Affiliated tissues include brain, subthalamic nucleus and eye, and related phenotypes are cellular and behavior/neurological

Wikipedia : 74 Parkinsonism is a clinical syndrome characterized by tremor, bradykinesia, rigidity, and postural... more...

Related Diseases for Parkinsonism

Diseases in the Parkinsonism family:

Atp13a2-Related Parkinsonism

Diseases related to Parkinsonism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 917)
# Related Disease Score Top Affiliating Genes
1 dystonia 3, torsion, x-linked 32.9 TAF1 ATP1A3
2 dystonia, dopa-responsive 32.3 TAF1 SLC6A3 ATP1A3
3 frontotemporal dementia 32.2 SNCA MAPT LRRK2 ATXN2
4 postencephalitic parkinson disease 32.1 SNCA SLC6A3 PARK7 MAPT LRRK2
5 multiple system atrophy 1 32.0 SNCA SLC6A3 MAPT LRRK2
6 dystonia 12 32.0 TAF1 SLC39A14 SLC30A10 PINK1 PARK7 ATP1A3
7 kufor-rakeb syndrome 31.9 SNCA SLC6A3 PINK1 PARK7 LRRK2
8 parkinson disease 2, autosomal recessive juvenile 31.6 SNCA PINK1 PARK7 MT-ND6 LRRK2
9 hypermanganesemia with dystonia 31.5 SLC39A14 SLC30A10
10 neuronal intranuclear inclusion disease 31.4 SNCA MAPT
11 parkinson disease 6, autosomal recessive early-onset 31.4 PINK1 PARK7 MT-ND6
12 neurodegeneration with brain iron accumulation 31.3 SNCA SLC39A14 PINK1 PARK7 ATP1A3
13 parkinson disease 1, autosomal dominant 31.3 SNCA MAPT LRRK2 ATXN2
14 supranuclear palsy, progressive, 1 31.2 SNCA SLC6A3 PINK1 PARK7 MAPT LRRK2
15 amyotrophic lateral sclerosis 1 31.2 SNCA SLC6A3 PINK1 PARK7 MAPT LRRK2
16 tremor 31.1 SNCA MAPT LRRK2 LOC106627981
17 von economo's disease 30.8 SNCA LRRK2
18 dementia, lewy body 30.8 SNCA SLC6A3 PINK1 PARK7 MAPT LRRK2
19 amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 30.7 TRPM7 TBC1D24 SNCA PARK7 MT-ND6 MAPT
20 essential tremor 30.7 SNCA SLC6A3 MAPT LRRK2
21 mutism 30.7 SLC6A3 MAPT ATP1A3
22 apraxia 30.7 SLC6A3 POLG MAPT
23 aphasia 30.7 SNCA MAPT LRRK2
24 akinetic mutism 30.6 SNCA SLC6A3 MAPT
25 sleep disorder 30.4 SNCA SLC6A3 MAPT LRRK2
26 choreatic disease 30.4 SNCA SLC6A3 PINK1 ATXN2 ATP1A3
27 parkinson disease 4, autosomal dominant 30.4 SNCA SLC6A3
28 early-onset parkinson's disease 30.4 SNCA PINK1 PARK7 LRRK2
29 rem sleep behavior disorder 30.3 SNCA SLC6A3 PINK1 MAPT LRRK2
30 machado-joseph disease 30.3 SNCA SLC6A3 ATXN2
31 hemidystonia 30.2 TAF1 ATP1A3
32 pick disease of brain 30.2 SNCA PARK7 MAPT LRRK2
33 gaucher's disease 30.1 SNCA PINK1 PARK7 LRRK2 LOC106627981
34 olivopontocerebellar atrophy 30.1 SNCA SLC6A3 MAPT ATXN2
35 arteriolosclerosis 30.0 SNCA MAPT
36 communicating hydrocephalus 30.0 SNCA SLC6A3 MAPT
37 parkinson disease 3, autosomal dominant 30.0 SNCA PARK7 MAPT LRRK2
38 ideomotor apraxia 30.0 SNCA MAPT
39 speech disorder 30.0 SLC6A3 MAPT LOC106627981
40 parkinson disease, late-onset 29.9 TAF1 SNCA SLC6A3 POLG PINK1 PARK7
41 autosomal dominant cerebellar ataxia 29.8 SNCA POLG PINK1 PARK7 MAPT LRRK2
42 restless legs syndrome 29.8 SNCA SLC6A3 MAPT ATXN2
43 parkinson disease 17 29.8 SNCA PARK7
44 prion disease 29.8 SNCA PINK1 PARK7 MAPT LRRK2
45 3-methylglutaconic aciduria, type iii 29.7 POLG PINK1 MT-ND6 LRRK2
46 peripheral nervous system disease 29.6 SNCA POLG PINK1 MT-ND6 MAPT LRRK2
47 nervous system disease 29.6 SNCA SLC6A3 PINK1 MAPT LRRK2
48 dementia 29.5 TRPM7 SNCA SLC6A3 PINK1 PARK7 MAPT
49 speech and communication disorders 29.5 SNCA SLC6A3 MAPT
50 early myoclonic encephalopathy 29.4 TBC1D24 POLG MT-ND6

Graphical network of the top 20 diseases related to Parkinsonism:



Diseases related to Parkinsonism

Symptoms & Phenotypes for Parkinsonism

MGI Mouse Phenotypes related to Parkinsonism:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.21 ATP6AP2 LRRK2 MAPT MT-ND6 PARK7 PINK1
2 behavior/neurological MP:0005386 10.2 ATP1A3 ATXN2 LRRK2 MAPT PARK7 PINK1
3 growth/size/body region MP:0005378 10.18 ATP1A3 ATXN2 MAPT MT-ND6 PARK7 PINK1
4 homeostasis/metabolism MP:0005376 10.17 ATP1A3 ATP6AP2 ATXN2 LRRK2 MAPT MT-ND6
5 mortality/aging MP:0010768 10.07 ATP1A3 ATP6AP2 ATXN2 LRRK2 MAPT PINK1
6 endocrine/exocrine gland MP:0005379 10.01 ATXN2 LRRK2 PINK1 POLG SLC30A10 SLC6A3
7 nervous system MP:0003631 9.8 ATP1A3 ATP6AP2 ATXN2 LRRK2 MAPT MT-ND6
8 muscle MP:0005369 9.7 ATP1A3 ATP6AP2 MAPT MT-ND6 POLG SLC39A14
9 taste/olfaction MP:0005394 8.92 MAPT PINK1 SLC6A3 SNCA

Drugs & Therapeutics for Parkinsonism

Drugs for Parkinsonism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 449)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
2
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
3
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 26757 5195
4
Amantadine Approved Phase 4 768-94-5 2130
5
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
6
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585 135398745
7
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
8
Donepezil Approved Phase 4 120014-06-4 3152
9
Benserazide Approved, Investigational Phase 4 322-35-0
10
Sulfamethazine Approved, Investigational, Vet_approved Phase 4 57-68-1 5327
11
Domperidone Approved, Investigational, Vet_approved Phase 4 57808-66-9 3151
12
Opicapone Approved, Investigational Phase 4 923287-50-7
13
Sodium citrate Approved, Investigational Phase 4 68-04-2
14
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
15
Mirabegron Approved Phase 4 223673-61-8 9865528
16
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
17
Trimethobenzamide Approved, Investigational Phase 4 138-56-7 5577
18
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
19
Pimavanserin Approved, Investigational Phase 4 706779-91-1 16058810
20
Droxidopa Approved, Investigational Phase 4 23651-95-8 443940
21
Zoledronic Acid Approved Phase 4 118072-93-8 68740
22
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
23
Promethazine Approved, Investigational Phase 4 60-87-7 4927
24
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
25
Suvorexant Approved, Investigational Phase 4 1030377-33-3
26
Apomorphine Approved, Investigational Phase 4 58-00-4, 41372-20-7 6005
27
Iodine Approved, Investigational Phase 4 7553-56-2 807
28
Memantine Approved, Investigational Phase 4 19982-08-2 4054
29
Amitriptyline Approved Phase 4 50-48-6 2160
30 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
31
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
32
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
33
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
34
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
35
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
36
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
37
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
38
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
39
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
40
Propranolol Approved, Investigational Phase 4 525-66-6 4946
41
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
42
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
43
Rizatriptan Approved Phase 4 144034-80-0, 145202-66-0 5078
44
Idebenone Approved, Investigational Phase 4 58186-27-9
45
Cabergoline Approved Phase 4 81409-90-7 54746
46
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
47
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
48
Rasagiline Approved Phase 4 136236-51-6 3052776
49
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
50
Acetylcholine Approved, Investigational Phase 4 51-84-3 187

Interventional clinical trials:

(show top 50) (show all 2651)
# Name Status NCT ID Phase Drugs
1 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Unknown status NCT01098383 Phase 4 Acetyl-Choline Esterase Inhibitors and Choline supplements;Indistinguishable placebo tablets, matching both donepezil and choline
2 Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled Trial Unknown status NCT02768077 Phase 4 Melatonin(Circadin®);Placebo
3 Nicotine Treatment of Impulsivity in Parkinson's Disease: A Pilot Study Unknown status NCT01216904 Phase 4 nicotine patch;placebo
4 The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Over 3 Months Unknown status NCT00696215 Phase 4 placebo;rasagiline
5 Effect of Deep Brain Stimulation on Gait of Patients With Parkinson's Disease Depending on Electrode Location in Subthalamic Area. Unknown status NCT01782638 Phase 4
6 Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study. Unknown status NCT01765257 Phase 4 AZILECT®;Placebo
7 Effects of Azilect (Rasagiline) on Processing of Emotions, Mood and Executive Function in Parkinson's Disease Unknown status NCT01385735 Phase 4 Rasagiline;Placebo
8 Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in Parkinson's Disease Patients With Delayed ON: a Multicenter Randomized Open-label Cross-over Trial Unknown status NCT02769793 Phase 4 Levodopa dispersible;Levodopa
9 A Randomized, Double-blind, Placebo Controlled, Crossover Study to Evaluate the Effect of Donepezil on Gait and Balance in Parkinson's Disease Unknown status NCT01521117 Phase 4 Donepezil
10 An Open-label, Randomized, Multi-center, Crossover Study to Observe the Effect of Once-daily Mirapex ER® and Twice-daily Mirapex ER® in Patients With Parkinson Disease Unknown status NCT01515774 Phase 4 Mirapex ER
11 An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction. Unknown status NCT02225548 Phase 4 Selegiline;Tadalafil
12 Effects of Different Concentrations of Dexmedetomidine on Basal Ganglia Neuronal Activity (Local Field Potentials) in Parkinson's Disease Unknown status NCT02982512 Phase 4 Dexmedetomidine
13 A Prospective Randomized Placebo-Controlled Double-Blind Study Assessing Change in Olfactory Function After Initiation of Rasagiline in Idiopathic Parkinson's Disease Unknown status NCT01007630 Phase 4 Rasagiline;Placebo
14 Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease Characterized by Postural Instability and Gait Disturbance Unknown status NCT03011476 Phase 4 Donepezil;Placebos
15 Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled Trial Unknown status NCT03258294 Phase 4 Melatonin(Circadin®);Placebo Oral Tablet
16 A Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot Study Unknown status NCT02472210 Phase 4 Botulinum Toxin
17 The Use of Toxin Botulinum A Toxin in Patients With Parkinson's Disease and Multiple System Disease, Affected by Refractory Detrusor Overactivity. Unknown status NCT00822913 Phase 4 Intravesical injection of Botulinum A toxin
18 A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease Unknown status NCT03034564 Phase 4 Northera;Placebo Oral Tablet
19 An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease Unknown status NCT03034538 Phase 4 Zonegran;Zonegran
20 Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease: a Randomised, Double-blind, Placebo-controlled Trial. Unknown status NCT03195231 Phase 4 Wuling Powder;Placebo
21 Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease: a Double-blind, Randomized Placebo-controlled Trial Unknown status NCT03412513 Phase 4 Mirabegron;Placebo
22 Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients. Unknown status NCT01780467 Phase 4
23 A Double Blind, Placebo-controlled Study for the Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy Unknown status NCT01313819 Phase 4 PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj
24 A Multicenter, Open-Label, Two-Arm Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management Completed NCT03103919 Phase 4 Rotigotine
25 A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 3-Arm, Phase 4 Study To Evaluate The Efficacy Of Rotigotine On Parkinson's Disease-Associated Apathy, Motor Symptoms, And Mood Completed NCT01782222 Phase 4 Rotigotine
26 Multicenter, Double-blind, Placebo-controlled, Parallel-group, Phase IV Study to Assess the Effect of Rotigotine on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease Completed NCT01300819 Phase 4 Rotigotine
27 Double Blind, Placebo-controlled, Parallel, Multicenter, Randomized Interventional Phase IV Study to Evaluate the Efficacy of Rotigotine on Depressive Symptoms in Idiopathic Parkinson's Disease Patients Completed NCT01523301 Phase 4 Rotigotine;Placebo
28 A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release (PR) in Patients With Early Stage Parkinson's Disease Completed NCT01485172 Phase 4 ropinirole monotherapy;placebo monotherapy
29 A Multicentre, Randomised, Open Label, Comparative Phase 4 Trial to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism in a General Neurologist Setting. Completed NCT00382967 Phase 4
30 A Randomized Controlled Trial Study of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism Completed NCT00331825 Phase 4 Risperidone and Olanzapine
31 Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) Completed NCT00043849 Phase 4 Quetiapine
32 A Phase IV Randomized, Double-Blind, Placebo-Controlled, Crossover Single Site Study Of Exelon® Patch (Rivastigmine Transdermal System) For Mild Cognitive Impairment In Parkinson's Disease Completed NCT01519271 Phase 4 Exelon Patch (rivastigmine transdermal system);Placebo Patches
33 The REmission of the Impulse Control Disorder and the Changes of the Neuropsychiatric Characteristics After Switching Into Levodopa/Carbidopa in Patients With Parkinson's Disease Who Have Developed Impulse Control Disorders Due to the Dopamine Replacement Therapy Completed NCT01683253 Phase 4 Levodopa/Carbidopa(200mg/50mg);Dopaminergic Agonists
34 Effects of Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity (Local Field Potentials) Measured Through Implanted Stimulators Completed NCT02256319 Phase 4 Dexmedetomidine;Propofol
35 Onabotulinum Toxin Type A (BTX-A) For Treatment of Neurogenic Overactive Bladder Due to Parkinson's Disease: Safety and Efficacy Completed NCT01421719 Phase 4 Cystoscopic injection of Botox into the urinary bladder
36 Effect of Short-term Motilitone Therapy on Health-related Quality of Life in Parkinson's Disease Patients With Gastrointestinal Symptoms: a Multicenter, Double-blind Randomized, Placebo-controlled Trial Completed NCT02775591 Phase 4 DA-9701;DA-9701 placebo
37 A Two- Stage Multicenter, Open-label, Randomized, Active Controlled Parallel Group Study Comparing the Efficacy and Safety of Pramipexole SR Versus Pramipexole IR Administered Orally Over an 18-week Treatment on Nocturnal Symptoms in L-Dopa+ Treated Patients With Advanced Parkinson's Disease (PD) Completed NCT03521635 Phase 4 Pramipexole SR;Pramipexole IR
38 Open-label, Multicenter, Effectiveness and Safety Study of Once Daily AZILECT® as Mono- or Adjunct Therapy in Patients With Idiopathic Parkinson's Disease (PD) Completed NCT00399477 Phase 4 rasagiline mesylate;Rasagiline mesylate plus Mirapex;Rasagiline mesylate with Levodopa;Rasagiline mesylate with Requip
39 Influence of Catechol-O-methyltransferase Polymorphism on Entacapone Efficacy in Parkinson's Disease Completed NCT00373087 Phase 4 entacapone;l dopa versus placebo
40 A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Examine the Efficacy and Safety of Early Pramipexole (PPX) Treatment Versus Delayed Pramipexole Treatment in Patients With New Onset Parkinson's Disease. Completed NCT00321854 Phase 4 pramipexole
41 Continuous Delivery of Levodopa/Carbidopa (Duodopa) in Patients With Advanced Idiopathic Parkinsons Disease - a Health Economic Evaluation Completed NCT00272688 Phase 4 Levodopa (drug), intraduodenal administration
42 Randomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
43 A Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of Rasagiline as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson's Disease Completed NCT01049984 Phase 4 Rasagiline;Placebo
44 URGE-PD: A Multi-site, Double-blind, Randomized, Placebo Controlled Trial of Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease Completed NCT01018264 Phase 4 solifenacin succinate (VESIcare);placebo
45 A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease Completed NCT01723228 Phase 4 Rasagiline;Placebo
46 The Effect of Rasagiline on Cognition in Parkinson's Disease Completed NCT01382342 Phase 4 Rasagiline;Placebo
47 Motor Response to Acute Challenge to Sildenafil in Parkinsons Disease Completed NCT01941732 Phase 4 Sildenafil
48 Depression Diagnosis and Treatment in Parkinson Disease Completed NCT00304161 Phase 4 Atomoxetine;Placebo
49 A Randomized, Double-blind, Placebo-controlled, Parallel Group Efficacy Study of Pramipexole and Placebo Administered Orally Over a 12 Week Treatment Phase in Parkinson's Disease Patients With Stable Motor Function and Depressive Symptoms Completed NCT00297778 Phase 4 Pramipexole
50 A Prospective, Multi-center, Randomized, Open-label Study With Blinded Raters to Evaluate the Effects of Immediate Versus Delayed Switch to Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-dose Wearing Off Completed NCT00219284 Phase 4 Carbidopa/levodopa/entacapone

Search NIH Clinical Center for Parkinsonism

Genetic Tests for Parkinsonism

Anatomical Context for Parkinsonism

MalaCards organs/tissues related to Parkinsonism:

40
Brain, Subthalamic Nucleus, Eye, Cortex, Globus Pallidus, Spinal Cord, Bone Marrow

Publications for Parkinsonism

Articles related to Parkinsonism:

(show top 50) (show all 17379)
# Title Authors PMID Year
1
Narcolepsy in Parkinson's disease. 61 54
20518604 2010
2
Comment on "compound heterozygosity in DJ-1 gene non-coding portion related to Parkinsonism". 61 54
20227322 2010
3
Glucocerebrosidase mutations are not a common risk factor for Parkinson disease in North Africa. 54 61
19945510 2010
4
POLG1 polyglutamine tract variants associated with Parkinson's disease. 61 54
20399836 2010
5
Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy. 61 54
20457763 2010
6
DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function. 54 61
20457924 2010
7
The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. 61 54
20425034 2010
8
Degenerative parkinsonism in patients with psychogenic parkinsonism: A dopamine transporter imaging study. 54 61
20061077 2010
9
LRRK2 and Parkinson disease. 54 61
20457952 2010
10
Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein. 54 61
20193038 2010
11
Identification and characterization of a novel endogenous murine parkin mutation. 61 54
20089136 2010
12
Lysosomal degradation of alpha-synuclein in vivo. 61 54
20200163 2010
13
Synergistic anti-Parkinsonism activity of high doses of B vitamins in a chronic cellular model. 61 54
18639366 2010
14
A pivotal role for PINK1 and autophagy in mitochondrial quality control: implications for Parkinson disease. 54 61
20385539 2010
15
The mitochondrial fusion-promoting factor mitofusin is a substrate of the PINK1/parkin pathway. 61 54
20383334 2010
16
Increased interaction between DJ-1 and the Mi-2/ nucleosome remodelling and deacetylase complex during cellular stress. 61 54
20127688 2010
17
[Establishment and application of an analytical method for PINK1 gene exon copy number]. 61 54
20376796 2010
18
Parkinson's disease: insights from pathways. 61 54
20421364 2010
19
In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study. 61 54
20043906 2010
20
Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau. 61 54
20127702 2010
21
alpha-Synuclein multiplication analysis in Italian familial Parkinson disease. 54 61
19833540 2010
22
SCA17 repeat expansion: mildly expanded CAG/CAA repeat alleles in neurological disorders and the functional implications. 54 61
20004653 2010
23
Genetic screening reveals high frequency of PARK2 mutations and reduced Parkin expression conferring risk for Parkinsonism in North West India. 61 54
19734163 2010
24
The role of imaging in the diagnosis of vascular parkinsonism. 54 61
19959019 2010
25
Differential neuropsychological profiles in Parkinsonian patients with or without vascular lesions. 54 61
20014112 2010
26
Neurodegenerative dementia and parkinsonism. 61 54
20082052 2010
27
Tickled PINK1: mitochondrial homeostasis and autophagy in recessive Parkinsonism. 54 61
19595762 2010
28
Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. 61 54
19903734 2010
29
The role of DAT-SPECT in movement disorders. 61 54
20019219 2010
30
'Prion-like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy. 54 61
20160454 2010
31
The biology and pathology of the familial Parkinson's disease protein LRRK2. 61 54
20187256 2010
32
Synphilin-1 exhibits trophic and protective effects against Rotenone toxicity. 54 61
19857556 2010
33
Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease. 61 54
19815446 2009
34
Clinical features of LRRK2 parkinsonism. 54 61
20082991 2009
35
The PINK1/Parkin pathway: a mitochondrial quality control system? 54 61
19967438 2009
36
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. 54 61
19915576 2009
37
Involvement of puromycin-sensitive aminopeptidase in proteolysis of tau protein in cultured cells, and attenuated proteolysis of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) mutant tau. 61 54
20377816 2009
38
Alpha-synuclein polymorphisms are associated with Parkinson's disease in a Saskatchewan population. 54 61
19890971 2009
39
Small CGG repeat expansion alleles of FMR1 gene are associated with parkinsonism. 54 61
19796183 2009
40
Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-dopa PET progression study. 61 54
19845000 2009
41
[Clinical, pathological, and genetic characteristics of frontotemporal dementia and parkinsonism linked to chromosome 17 with mutations in the MAPT and PGRN]. 54 61
19938685 2009
42
The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews. 54 61
19756366 2009
43
The role of PTEN-induced kinase 1 in mitochondrial dysfunction and dynamics. 61 54
19703660 2009
44
Enhanced alpha-synuclein expression in human neurodegenerative diseases: pathogenetic and therapeutic implications. 54 61
19538156 2009
45
Nitroindazole compounds inhibit the oxidative activation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to neurotoxic pyridinium cations by human monoamine oxidase (MAO). 54 61
19669997 2009
46
Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. 54 61
19741132 2009
47
Expanding the clinical phenotype of SNCA duplication carriers. 61 54
19562770 2009
48
Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy. 61 54
19405128 2009
49
Parkin promotes intracellular Abeta1-42 clearance. 54 61
19483198 2009
50
Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy. 54 61
19680561 2009

Variations for Parkinsonism

ClinVar genetic disease variations for Parkinsonism:

6 (show all 17)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TBC1D24 NM_001199107.2(TBC1D24):c.1078C>T (p.Arg360Cys) SNV Pathogenic 375707 rs1057519629 16:2548333-2548333 16:2498332-2498332
2 TBC1D24 NM_001199107.2(TBC1D24):c.404C>T (p.Pro135Leu) SNV Pathogenic 375708 rs1057519630 16:2546553-2546553 16:2496552-2496552
3 LOC106627981 NM_000157.4(GBA):c.1093G>A (p.Glu365Lys) SNV risk factor 199044 rs2230288 1:155206167-155206167 1:155236376-155236376
4 LOC106627981 NM_000157.4(GBA):c.1093G>A (p.Glu365Lys) SNV risk factor 199044 rs2230288 1:155206167-155206167 1:155236376-155236376
5 LOC106627981 NM_000157.4(GBA):c.1093G>A (p.Glu365Lys) SNV risk factor 199044 rs2230288 1:155206167-155206167 1:155236376-155236376
6 LOC106627981 NM_000157.4(GBA):c.1448T>C (p.Leu483Pro) SNV risk factor 4288 rs421016 1:155205043-155205043 1:155235252-155235252
7 MT-ND6 NC_012920.1:m.14598T>C SNV Likely pathogenic 374080 rs1057518882 MT:14598-14598 MT:14598-14598
8 PDGFRB NM_002609.4(PDGFRB):c.3241G>A (p.Glu1081Lys) SNV Uncertain significance 523454 rs1554107047 5:149495406-149495406 5:150115843-150115843
9 MRE11 NM_005591.3(MRE11):c.1727G>A (p.Arg576Gln) SNV Uncertain significance 127974 rs139461096 11:94180441-94180441 11:94447275-94447275
10 MRE11 NM_005591.3(MRE11):c.229G>A (p.Glu77Lys) SNV Uncertain significance 481777 rs779269083 11:94219175-94219175 11:94486009-94486009
11 LRRK2 NM_198578.4(LRRK2):c.5647T>C (p.Phe1883Leu) SNV Uncertain significance 373908 rs762890407 12:40717099-40717099 12:40323297-40323297
12 LOC106627981 NM_000157.4(GBA):c.1279G>A (p.Glu427Lys) SNV Uncertain significance 493050 rs149171124 1:155205581-155205581 1:155235790-155235790
13 CSF1R NM_001288705.2(CSF1R):c.647G>A (p.Arg216Gln) SNV Uncertain significance 374038 rs750413238 5:149457757-149457757 5:150078194-150078194
14 ADCY5 NM_183357.2(ADCY5):c.649del (p.Arg217fs) Deletion Uncertain significance 373900 rs1057518757 3:123166744-123166744 3:123447897-123447897
15 TGM6 NM_198994.3(TGM6):c.76C>T (p.Pro26Ser) SNV Uncertain significance 523569 rs766248910 20:2375166-2375166 20:2394520-2394520
16 MT-CYB NC_012920.1:m.15127C>T SNV Uncertain significance 370064 rs1057516074 MT:15127-15127 MT:15127-15127
17 TYROBP NM_003332.3(TYROBP):c.94G>A (p.Asp32Asn) SNV Uncertain significance 374122 rs758290972 19:36398632-36398632 19:35907730-35907730

Expression for Parkinsonism

Search GEO for disease gene expression data for Parkinsonism.

Pathways for Parkinsonism

Pathways related to Parkinsonism according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.1 SNCA SLC6A3 PINK1 PARK7 MT-ND6 MAPT
2 12.3 SNCA PINK1 PARK7 MAPT LRRK2
3
Show member pathways
12.24 SNCA SLC6A3 POLG PINK1 PARK7 ATXN2
4
Show member pathways
12.22 SNCA SLC6A3 PINK1 PARK7 MT-ND6 MAPT
5 11.02 SNCA SLC6A3 PINK1 PARK7 LRRK2 ATXN2
6 10.94 SNCA SLC6A3 PARK7

GO Terms for Parkinsonism

Cellular components related to Parkinsonism according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.25 TRPM7 TBC1D24 SNCA SLC6A3 SLC39A14 SLC30A10
2 membrane GO:0016020 10.2 TRPM7 TBC1D24 SNCA SLC6A3 SLC39A14 SLC30A10
3 mitochondrion GO:0005739 10.04 SNCA POLG PINK1 PARK7 MT-ND6 MAPT
4 synapse GO:0045202 9.91 TBC1D24 SNCA PARK7 LRRK2 ATP6AP2 ATP1A3
5 neuron projection GO:0043005 9.8 SLC6A3 PARK7 MAPT LRRK2 ATP6AP2
6 neuronal cell body GO:0043025 9.77 SNCA SLC6A3 MAPT LRRK2 ATP1A3
7 membrane raft GO:0045121 9.76 SLC6A3 PARK7 MAPT LRRK2
8 mitochondrial intermembrane space GO:0005758 9.65 SNCA PINK1 PARK7
9 growth cone GO:0030426 9.56 SNCA PINK1 MAPT LRRK2
10 inclusion body GO:0016234 9.52 SNCA LRRK2
11 cell body GO:0044297 9.46 PINK1 PARK7 MAPT ATP6AP2
12 terminal bouton GO:0043195 9.26 TBC1D24 SNCA POLG LRRK2
13 axon GO:0030424 9.23 SNCA SLC6A3 PINK1 PARK7 MAPT LRRK2

Biological processes related to Parkinsonism according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.92 TAF1 PINK1 PARK7 MAPT
2 mitochondrion organization GO:0007005 9.77 PINK1 PARK7 LRRK2
3 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.76 SNCA PINK1 PARK7
4 negative regulation of neuron apoptotic process GO:0043524 9.73 SNCA SLC30A10 PINK1 PARK7
5 negative regulation of protein phosphorylation GO:0001933 9.72 SNCA PARK7 LRRK2
6 zinc ion transport GO:0006829 9.67 SLC39A14 SLC30A10
7 regulation of reactive oxygen species metabolic process GO:2000377 9.67 SNCA PINK1
8 protein tetramerization GO:0051262 9.66 TRPM7 SNCA
9 regulation of neuron apoptotic process GO:0043523 9.66 PINK1 PARK7
10 regulation of neuron death GO:1901214 9.65 SNCA LRRK2
11 zinc ion transmembrane transport GO:0071577 9.65 SLC39A14 SLC30A10
12 stress granule assembly GO:0034063 9.65 MAPT ATXN2
13 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.64 PARK7 LRRK2
14 negative regulation of reactive oxygen species biosynthetic process GO:1903427 9.64 SLC30A10 PARK7
15 negative regulation of autophagosome assembly GO:1902902 9.63 PINK1 LRRK2
16 negative regulation of macroautophagy GO:0016242 9.63 PINK1 LRRK2
17 response to cocaine GO:0042220 9.63 SNCA SLC6A3 MT-ND6
18 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.62 PARK7 LRRK2
19 negative regulation of oxidative stress-induced neuron death GO:1903204 9.61 PINK1 PARK7
20 supramolecular fiber organization GO:0097435 9.61 SNCA MAPT
21 synaptic transmission, dopaminergic GO:0001963 9.59 SNCA PARK7
22 negative regulation of oxidative stress-induced cell death GO:1903202 9.58 PINK1 PARK7
23 manganese ion transmembrane transport GO:0071421 9.57 SLC39A14 SLC30A10
24 dopamine biosynthetic process GO:0042416 9.56 SNCA SLC6A3
25 regulation of mitochondrial fission GO:0090140 9.54 MAPT LRRK2
26 intracellular distribution of mitochondria GO:0048312 9.52 MAPT LRRK2
27 regulation of locomotion GO:0040012 9.51 SNCA LRRK2
28 positive regulation of histone deacetylase activity GO:1901727 9.49 PINK1 LRRK2
29 negative regulation of mitochondrial fission GO:0090258 9.48 PINK1 MAPT
30 cellular response to oxidative stress GO:0034599 9.46 SNCA PINK1 PARK7 LRRK2
31 positive regulation of androgen receptor activity GO:2000825 9.4 TAF1 PARK7
32 positive regulation of mitochondrial electron transport, NADH to ubiquinone GO:1902958 9.37 PINK1 PARK7
33 regulation of synaptic vesicle transport GO:1902803 9.32 PINK1 LRRK2
34 negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway GO:1903384 9.26 PINK1 PARK7
35 negative regulation of neuron death GO:1901215 9.26 SNCA PINK1 PARK7 LRRK2
36 dopamine uptake involved in synaptic transmission GO:0051583 8.8 SNCA SLC6A3 PARK7

Molecular functions related to Parkinsonism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein serine/threonine kinase activity GO:0004674 9.67 TRPM7 TAF1 PINK1 LRRK2
2 actin binding GO:0003779 9.56 TRPM7 SNCA MAPT LRRK2
3 protease binding GO:0002020 9.33 SLC6A3 POLG PINK1
4 zinc ion transmembrane transporter activity GO:0005385 9.32 SLC39A14 SLC30A10
5 cuprous ion binding GO:1903136 8.96 SNCA PARK7
6 manganese ion transmembrane transporter activity GO:0005384 8.62 SLC39A14 SLC30A10

Sources for Parkinsonism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....